iron sucrose

CLINICAL USE

Prophylaxis of iron deficiency anaemia (when oral treatment is ineffective or contraindicated) Treatment of iron deficiency during epoetin therapy especially if serum ferritin is very low (<50 nanograms/mL)

DOSE IN NORMAL RENAL FUNCTION

According to local protocol.

PHARMACOKINETICS

  • Molecular weight                           :34 000–60 000
  • %Protein binding                           :No data
  • %Excreted unchanged in urine     : <5
  • Volume of distribution (L/kg)       :8 litres
  • half-life – normal/ESRD (hrs)      :6

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Not dialysed. Dose as in normal renal function
  • HD                     :Not dialysed. Dose as in normal renal function
  • HDF/high flux   :Not dialysed. Dose as in normal renal function
  • CAV/VVHD      :Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsDimercaprol: avoid concomitant use Do not administer with oral iron

    ADMINISTRATION

    Reconstition

    Route

    IV

    Rate of Administration

    Bolus: 1 mL/minute Infusion: in sodium chloride 0.9% at a concentration of 1 mg/mL over 20–30 minutes per 100 mg

    Comments

    A test dose is required before administrationDoses can be administered via the venous limb of the dialysis machineStable for 24 hours at room temperature

    OTHER INFORMATION

    Some regimes are: 50–300 mg weekly —100 mg once or twice monthly —20–40 mg with each dialysis —Oral iron can be restarted 5 days after completion of the course of IV iron

  • Related News